Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Lajos Pusztai MD
Open to Accrual
To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either ≥1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset
Protocol DocumentsThe protocol and related documents are available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Note: This study is a collaboration between SWOG and NRG Oncology. SWOG is the lead organization.
Patients with TNBC, ≥1cm residual invasive breast cancer, or any + LN after neoadjuvant chemotherapy, followed by surgery
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.